Ensign Q3: Revenue Up 14.5% to $1.48B, EPS Up 23.9%; New Securities Class Action Disclosed
ENSG sits 20% above its 52-week low of $141.58 on elevated volume (2.0× avg).
Summary
Ensign posted Q3 revenue of $1.48 billion (+14.5%) and diluted EPS of $1.76 (+23.9%), while formally disclosing a new securities class action filed October 8, 2026 and continued heavy acquisition spending that cut cash to $337.6 million.
Key Events · Earnings and Guidance · ENSG
-
Q3 Revenue and EPS Accelerate
Total revenue rose 14.5% to $1,484.0 million from $1,296.4 million, and diluted EPS rose 23.9% to $1.76 from $1.42; net income attributable to Ensign was $104.3 million versus $83.8 million.
-
Margins Improve on Cost Leverage
Cost of services fell to 78.6% of revenue from 80.6%, lifting income from operations to $138.0 million from $96.2 million; adjusted EBITDA was $190.7 million versus $151.1 million.
-
New Securities Class Action Disclosed
A putative class action (Perusek v. The Ensign Group, No. 8:26-cv-02963) was filed October 8, 2026 on behalf of purchasers between February 10, 2022 and June 18, 2026, alleging misstatements on regulatory compliance, staffing and CMS ratings; no loss has been accrued.
-
Cash Falls on Acquisition Spend
Cash and equivalents dropped to $337.6 million from $503.9 million at December 31, 2025, after $539.9 million of acquisition cash payments; nine-month operating cash flow was $512.3 million.
Analysis · ENSG · Industrial Applications And Services
Ensign's core business is accelerating: Q3 revenue rose 14.5% to $1.48 billion and diluted EPS jumped 23.9% to $1.76, with same-facility occupancy up 1.6 points to 84.1% and cost of services falling to 78.6% of revenue from 80.6%. The offset is legal: this 10-Q formally discloses a securities class action filed October 8, 2026 covering purchasers from February 2022 through June 2026, alongside the July derivative suit and the still-open DOJ civil investigative demand over Medicare and Texas Medicaid claims. No amounts are accrued for the new suits, so the tail risk is unquantified. Growth is being funded heavily from the balance sheet — $539.9 million of acquisition cash payments in nine months cut cash to $337.6 million from $503.9 million — and the company added 18 more skilled nursing operations plus two campuses after quarter-end, entering Florida.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 31% of the 1656 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.01%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ENSG was trading at $169.50 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $9.9B. The 52-week trading range was $141.58 to $218.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.